Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Micron Biomedical secures funds for needle-free vaccine development
This funding round was led by J2 Ventures and the Global Health Investment Corporation (GHIC). With this funding, the company’s total Series A equity value raised to over
This funding round was led by J2 Ventures and the Global Health Investment Corporation (GHIC). With this funding, the company’s total Series A equity value raised to over
The company is set to launch a multicentre Phase I trial in the US in the first quarter of this year. Axcynsis Therapeutics CEO Dr Zou Bin said:
BAFIERTAM will join TASCENSO ODT (fingolimod), Cycle’s other branded MS treatment. Both these therapies will be supported by Cycle’s hub programme, Cycle Vita. The company noted that, during
This designation is for Carteyva, an anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy, as a second-line treatment for adults with this disease. It is developed independently
SPRIM Global Investments and William Taylor Nominees jointly led the funding round, which will support the conduct of a Phase I trial of RheumaGen’s lead candidate, RG0401. Anticipated
The decision is intended for individuals with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), as assessed by an FDA-approved test. This marks offering a new
The ‘fully human’, immunoglobulin G4 (IgG4) antibody is tailored to target Protein S, aiming to restore balance in blood clotting and potentially serves as a ‘universal haemostatic therapy’
This marks the first NMPA-approved monoclonal antibody that targets gastric tumour cells expressing the biomarker CLDN18.2. The approval offers a new, highly targeted treatment option for individuals particularly
This decision follows the positive outcomes from the multicentre, open-label Phase II TRUST-I trial. The single-arm trial was instrumental in assessing the therapy’s tolerability, efficiency, and safety in
This strategic move involves a total payment of $18m and terminates prior agreements with VBI, including future milestone and royalty obligations. Under the terms of the agreement, Brii